Handel nachbörslich: 2.17 0.10 +4.83%

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten

Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts - Investing.com UK

Invesco S&P SmallCap Materials ETF (NASDAQ:PSCM) Short Interest Up 22.6% in September - Defense World

First Trust NASDAQ ABA Community Bank Index Fund (NASDAQ:QABA) Short Interest Update - Defense World

RF Acquisition Corp. (NASDAQ:RFAC) Short Interest Update - Defense World

Nordstrom, Inc. (NYSE:JWN) Shares Sold by Axa S.A. - Defense World

Employees Retirement System of Texas Makes New Investment in Nova Ltd. (NASDAQ:NVMI) - Defense World

FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology - MyChesCo

Firstsource Acquires Ascensos - MENAFN.COM

Firstsource acquires UK-based Ascensos for $56 million - The Economic Times

Angel Capital weaves passage to glory in Guineas Prelude - Horse Betting

19 Sundance Movies to Watch Before Seeing These Filmmakers’ New Fall 2024 Releases - Sundance Institute

First Taste: At Prelude, Southern-inspired flavors get the fine-dining spotlight. - 7x7

Prelude Therapeutics (NASDAQ:PRLD) Upgraded to Strong-Buy by HC Wainwright - MarketBeat

Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MyChesCo

Data clang on Street for Prelude but SMARCA2 overtures continue - BioWorld Online

Healthy Upside Potential: Prelude Therapeutics Inc (PRLD) - SETE News

Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MyChesCo

Prelude Therapeutics Inc (PRLD) deserves closer scrutiny - US Post News

Prelude Therapeutics (NASDAQ:PRLD) Receives “Market Outperform” Rating from JMP Securities - Defense World

A Closer Look at Prelude Therapeutics Inc (PRLD) Stock Gains - The InvestChronicle

Glioblastoma Treatment Drugs, Pipeline Insights, Emerging Therapies, and Companies 2024 - openPR

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate - Simply Wall St

Ratios Reveal: Breaking Down Prelude Therapeutics Inc (PRLD)’s Financial Health - The Dwinnex

Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment - MyChesCo

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - Yahoo Finance

Prelude Therapeutics (NASDAQ:PRLD) Receives Neutral Rating from HC Wainwright - Defense World

Prelude Therapeutics Unveils Promising Data on PRT3789 at ESMO Congress 2024 - MyChesCo

Prelude Therapeutics' (PRLD) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat

Prelude Therapeutics (NASDAQ:PRLD) Shares Up 2.3% - MarketBeat

Prelude reports safety of new cancer drug at ESMO Congress By Investing.com - Investing.com Canada

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 - Yahoo Finance

SFA Therapeutics Appoints Dr. Ananda Gubbi as Director of Biostatistics to Enhance Drug Development - MyChesCo

Glioblastoma Pipeline Drugs, Treatment Therapies, Clinical Trials, and Companies 2024 - openPR

A Look at Prelude Therapeutics Inc (PRLD) Shares in the Recent Past Indicates Growth - SETE News

Financial Metrics Check: Prelude Therapeutics Inc (PRLD)’s Ratios for Trailing Twelve Months - The Dwinnex

Prelude Therapeutics Inc (PRLD) did well last session? - US Post News

MSD discontinues two Phase III Keytruda trials - Clinical Trials Arena

Windtree Therapeutics Reports Second-Quarter Financial Results and Key Business Updates - MyChesCo

Glioblastoma Pipeline Drugs 2024 | Denovo BioPharma, Pfizer, - openPR

The Globe and Mail - The Globe and Mail

HC Wainwright Equities Analysts Lower Earnings Estimates for Prelude Therapeutics Incorporated (NASDAQ:PRLD) - MarketBeat

Vanguard Group Inc. Raises Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Vanguard Group Inc. Buys 10,143 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

HC Wainwright Weighs in on Prelude Therapeutics Incorporated’s Q1 2025 Earnings (NASDAQ:PRLD) - Defense World

Prelude Therapeutics (NASDAQ:PRLD) Rating Reiterated by HC Wainwright - Defense World

Prelude Therapeutics Incorporated Forecasted to Post Q1 2025 Earnings of ($0.49) Per Share (NASDAQ:PRLD) - MarketBeat

HC Wainwright Reaffirms Neutral Rating for Prelude Therapeutics (NASDAQ:PRLD) - MarketBeat

Pathos AI Licenses PRT811 From Prelude Therapeutics - Contract Pharma

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 46.0% in July - MarketBeat

Prelude Therapeutics (NASDAQ:PRLD) Issues Quarterly Earnings Results, Meets Estimates - MarketBeat

PRLD stock soars to 52-week high, touches $6.8 amid growth - Investing.com India

Financial Review: Prelude Therapeutics (NASDAQ:PRLD) and Intra-Cellular Therapies (NASDAQ:ITCI) - Defense World

ArriVent BioPharma to Present Groundbreaking Data at 2024 World Conference on Lung Cancer - MyChesCo

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Progress in Clinical Trials - MyChesCo

Prelude Therapeutics Reports Q2 Financial Results and Key Clinical Developments - MyChesCo

Barclays cuts Prelude to underweight, cites lack of near-term catalysts - MSN

PRLD Stock Earnings: Prelude Therapeutics Misses EPS for Q2 2024 - InvestorPlace

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

Price T Rowe Associates Inc. MD Sells 100,766 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - MarketBeat

Context Therapeutics Appoints New Chief Medical Officer and VP of Clinical Operations - MyChesCo

PRLD Stock Soars to 52-Week High, Reaching $6.72 - Investing.com India

PRLD Stock Soars to 52-Week High, Reaching $6.72 - Investing.com

Acadian Asset Management LLC Acquires 6,615 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate - Yahoo Finance

Ähnlich wie PRLD